Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...
Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 ...
Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with ...
Mutuum Finance (MUTM) has entered a narrow phase of its roadmap where timing, visibility, and supply dynamics begin to overlap. Projects often reach moments where progress is no longer theoretical but ...
PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient ...
The Blazpay AI crypto presale has reached a major milestone, officially crossing $2.26 million raised as Phase 6 continues to ...
The IPF clinical trial is a Phase 2 randomized, double-blind, placebo-controlled, pilot study designed to evaluate the efficacy and safety of PRM-151 administered once-a-month to subjects with IPF.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback